Abstract A062: Selective USP10 inhibition by GL-458 re-sensitizes platinum-resistant non-small cell lung cancer through DNA damage response disruption
Platinum-based chemotherapy remains one of the standard treatments for advanced non-small cell lung cancer (NSCLC); however, most patients eventually relapse because of acquired resistance. A major driver of therapeutic resistance is hyperactivation of the DNA damage response (DDR), which allows tumor cells to repair...